Usp14 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
USP14 is a deubiquitinating enzyme (DUB) that plays a crucial role in the ubiquitin-proteasome system (UPS). It associates with the 26S proteasome and removes ubiquitin chains from substrates before their degradation. USP14 dysfunction is implicated in various neurodegenerative diseases due to its essential role in protein quality control and proteostasis [1]. [1]
USP14 is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of USP14 is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders. [2]
USP14 is a 1,070 amino acid protein with: [3]
The protein exists in both proteasome-bound and free cytosolic forms, with distinct functions in each compartment. [4]
USP14 removes ubiquitin chains from substrates:
USP14 modulates proteasome activity:
USP14 is highly expressed in neurons and regulates:
| Compound | Stage | Selectivity | Notes |
|---|---|---|---|
| IU1 | Preclinical | USP14-selective | First-generation inhibitor |
| IU1-47 | Preclinical | Improved potency | Enhanced brain penetration |
| WP1130 | Preclinical | Pan-DUB | Also inhibits USP9x, USP5 |
Inhibition approach:
Activation approach (controversial):
The study of Usp14 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Miale TD, et al. USP14 and neurodegeneration: the proteasome connection. 2016. ↩︎
Chen PC, et al. USP14 is a key regulator of proteostasis in neurodegeneration. 2019. ↩︎
Huang J, et al. USP14 inhibition reduces amyloid pathology in AD models. 2018. ↩︎
Liu H, et al. USP14 and ALS: a new therapeutic target. 2021. ↩︎